Video

Dr. Bekaii-Saab on the Importance of the ReDOS Study in mCRC

Tanios Bekaii-Saab, MD, professor of medicine, Mayo Clinic, discusses the importance of the phase II regorafenib (Stivarga) dose optimization study (ReDOS) in metastatic colorectal cancer (mCRC).

Tanios Bekaii-Saab, MD, professor of medicine, Mayo Clinic, discusses the importance of the phase II regorafenib (Stivarga) dose-optimization study (ReDOS) in metastatic colorectal cancer (mCRC).

The study randomized patients with mCRC to either the dose-escalation arm, which began at 80 mg per day and increased weekly up to 160 mg per day if no significant drug-related toxicities occurred, or the standard dose of 160 mg of regorafenib daily. This is now a preferred option of how to administer regorafenib, explains Bekaii-Saab.

According to Bekaii-Saab, there is now a strategy for physicians who are reluctant to start with 160 mg. Rather than doing guesswork, there is now a strategy that demonstrates that there is no loss in benefit by starting with a lower dose and escalating to 120 mg or 160 mg.

Related Videos
Sujith Samarasinghe, MD
Suzanne Trudel, MSc, MD
Consuelo Bertossi, MD
Michael R. Grunwald, MD, FACP
Sundar Jagannath, MBBS
Kevin Kalinsky, MD, MS,
Aaron Gerds, MD
Paolo Tarantino, MD
Chinmay Jani, MD, clinical fellow, Hematology & Oncology, Sylvester Comprehensive Cancer Center at the University of Miami/Jackson Memorial Hospital
Shella Saint Fleur-Lominy, MD, PhD